Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease.

Launched in 2016 after years of research supported by Stanford’s SPARK program, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

Biotechnology

Eidos Therapeutics

Neil Kumar

Suresh Siddhanti

Stuart Heminway

Satish Rao

Mamoun Alhamadsheh

Leonid K.

Jonathan Cascon

Janet Hsu

Isabella Graef

Ananth Sridhar

Jonathan Fox

Matt Outten

Uma Sinha

Clinical Research and Development

Leadership Team

Research and Development

Quality Assurance and Compliance

��

Teams at Eidos Therapeutics

Clinical Research and Development

Leadership Team

Research and Development

Quality Assurance and Compliance

��������

Teams at Eidos Therapeutics

Clinical Research and Development

Leadership Team

Research and Development

Quality Assurance and Compliance

��